UNICYCIVE THERAPEUTICS INC (UNCY)
US90466Y1038 - Common Stock
We assign a fundamental rating of 3 out of 10 to UNCY. UNCY was compared to 565 industry peers in the Biotechnology industry. While UNCY seems to be doing ok healthwise, there are quite some concerns on its profitability. UNCY has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
UNCY had negative earnings in the past year.
In the past year UNCY has reported a negative cash flow from operations.
UNCY had negative earnings in each of the past 5 years.
In the past 5 years UNCY always reported negative operating cash flow.
1.2 Ratios
UNCY has a Return On Assets of -62.47%. This is in the lower half of the industry: UNCY underperforms 60.25% of its industry peers.
UNCY has a Return On Equity (-86.52%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -62.47% | ||
| ROE | -86.52% | ||
| ROIC | N/A |
ROA(3y)-305.08%
ROA(5y)-2579.05%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
UNCY does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
UNCY does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, UNCY has more shares outstanding
The number of shares outstanding for UNCY has been increased compared to 5 years ago.
UNCY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
UNCY has an Altman-Z score of -1.48. This is a bad value and indicates that UNCY is not financially healthy and even has some risk of bankruptcy.
UNCY has a Altman-Z score (-1.48) which is in line with its industry peers.
UNCY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.48 |
ROIC/WACCN/A
WACC10.43%
2.3 Liquidity
A Current Ratio of 3.61 indicates that UNCY has no problem at all paying its short term obligations.
UNCY has a Current ratio of 3.61. This is comparable to the rest of the industry: UNCY outperforms 42.42% of its industry peers.
UNCY has a Quick Ratio of 3.61. This indicates that UNCY is financially healthy and has no problem in meeting its short term obligations.
UNCY has a Quick ratio (3.61) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.61 | ||
| Quick Ratio | 3.61 |
3. Growth
3.1 Past
The earnings per share for UNCY have decreased strongly by -34.17% in the last year.
UNCY shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)-34.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64.58%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
UNCY is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.33% yearly.
UNCY is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 233.05% yearly.
EPS Next Y53.75%
EPS Next 2Y36.95%
EPS Next 3Y38.32%
EPS Next 5Y22.33%
Revenue Next Year-100%
Revenue Next 2Y696.29%
Revenue Next 3Y755.86%
Revenue Next 5Y233.05%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
UNCY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for UNCY. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as UNCY's earnings are expected to grow with 38.32% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.95%
EPS Next 3Y38.32%
5. Dividend
5.1 Amount
No dividends for UNCY!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
UNICYCIVE THERAPEUTICS INC
NASDAQ:UNCY (11/22/2024, 8:10:35 PM)
After market: 0.5421 +0.01 (+2.28%)0.53
+0 (+0.42%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap55.01M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -62.47% | ||
| ROE | -86.52% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.61 | ||
| Quick Ratio | 3.61 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-34.17%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y53.75%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y